A stunning result
Cardiologists had waited anxiously for months for details after preliminary announcements of the two drugs’ failures. According to Dr. Karol Watson, a director of UCLA’s preventive cardiology programme, the whole cardiovascular community was stunned.
Now the answer is clear: there was no evidence the drugs helped anyone. By every measure they were no better than placebo, and the results, Watson said, were about as neutral as they could be.
Two approaches, one failure
The two trials targeted different mechanisms of heart disease:
- The Horizon trial of Novartis’ pelacarsen aimed to lower Lp(a), a protein thought to promote blood clots and cause heart attacks and strokes.
- The Zeus trial of Novo Nordisk’s ziltivekimab, in 6,376 patients with severe heart disease, advanced kidney disease and a marker of inflammation, aimed to block the inflammatory protein IL-6.
- Although ziltivekimab did reduce inflammation, those taking it fared no better than those on placebo in any subgroup.
Novo Nordisk halted two other ziltivekimab studies in heart failure patients in September but continues to test it in heart attack patients, a study due to conclude next year.














